Provenance Record

Well-organized News piece (Overview / What We Know / What We Don't Know / Analysis format). 778 words, within the 400-1200 News range. The Analysis section correctly frames the chemotherapy-free design as the article's news hook without overstating clinical significance, and explicitly notes the therapy has not yet been tested in patients.

All 3 sources read from local gzip snapshots in sources/2026-07/fate-therapeutics-wins-fda-clearance-for-ft839-a-dual-car-t-cell-therapy-for-autoimmune-disease/ and sha256-verified against manifest.json (source-0: 78f65a0e..., source-1: 593d446b..., source-2: ee905564... — all matched). source-0 (GlobeNewswire, the original company press release) confirms every specific claim in the article: the CD19/CD38 dual-CAR mechanism, the 13 targeted genetic edits, the Phase 1/2 basket trial design without conditioning chemotherapy, the five initial autoimmune indications (rheumatoid arthritis, ANCA-associated vasculitis, idiopathic inflammatory myositis, SLE with/without nephritis, systemic sclerosis), the Sword & Shield/Alloimmune Defense Receptor + CD58 knockout mechanism, the clonal master iPSC bank manufacturing approach, the FT819 comparison, the planned investigator-initiated T1D/MS trials, and both direct quotes from Bob Valamehr — both quotes verified verbatim against the snapshot text. source-1 (BioSpace) is a syndicated republication of the identical GlobeNewswire press release text, independently confirming the same claims via a second outlet as the article's inline citations claim. source-2 (StockTitan) independently corroborates the five-indication list and additionally confirms the article's stock-move claim: the snapshot's Argus market-data panel states 'FATE +6.14% in the Jul 9 session' and 'In the Jul 9 session, FATE gained 6.14%,' matching the article's 'rose 6.14%' paraphrase exactly.

No fabrications or hallucinated specifics found. Every number (13 genetic edits, 5 indications, 6.14% share move), name (Bob Valamehr, Ph.D., M.B.A., President and CEO), and technical term (hnCD16, CD3 fusion receptor, TRAC knockout via 'About FT839'/multiplexed engineering section) traces to the cited sources. No orphan source URLs in body_markdown — all three submission sources are referenced inline.

Clean, well-sourced News submission. All three sources read and hash-verified from disk; every claim, quote, and figure in the article traces cleanly to the cited sources. No suspicious_patterns flagged in the manifest. Not human_requested. Approved without corrections.